Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ovid Therapeutics (OVID) Net Margin (2020 - 2025)

Ovid Therapeutics' Net Margin history spans 6 years, with the latest figure at 1345.82% for Q4 2025.

  • For Q4 2025, Net Margin changed N/A year-over-year to 1345.82%; the TTM value through Dec 2025 reached 240.13%, up 515416.0%, while the annual FY2025 figure was 240.13%, 443001.0% up from the prior year.
  • Net Margin reached 1345.82% in Q4 2025 per OVID's latest filing, up from 9210.61% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 5042.01% in Q2 2024 to a low of 107798.33% in Q3 2022.
  • Average Net Margin over 5 years is 11462.47%, with a median of 4831.43% recorded in 2025.
  • The largest YoY upside for Net Margin was 9747448bps in 2023 against a maximum downside of -1844658bps in 2023.
  • A 5-year view of Net Margin shows it stood at 11.76% in 2021, then soared by 56bps to 5.17% in 2022, then plummeted by -33bps to 6.88% in 2023, then plummeted by -117625bps to 8095.95% in 2024, then skyrocketed by 117bps to 1345.82% in 2025.
  • Per Business Quant, the three most recent readings for OVID's Net Margin are 1345.82% (Q4 2025), 9210.61% (Q3 2025), and 74.68% (Q2 2025).